Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Frequently asked questions
What sector does Interpace Biosciences, Inc. (IDXGD) operate in?
Interpace Biosciences, Inc. belongs to the Other sector and operates in the Diagnostics & Research industry.
What is Interpace Biosciences, Inc. (IDXGD) current stock price?
As of the latest data, Interpace Biosciences, Inc. stock price is $6.39, with a previous close of $6.39.
What is Interpace Biosciences, Inc. (IDXGD) current market capitalization?
Interpace Biosciences, Inc. market cap is approximately 35.40 million.
What is Interpace Biosciences, Inc. (IDXGD) Earnings Per Share (EPS)?
The trailing EPS is $4.50.
What is Interpace Biosciences, Inc. (IDXGD) Price-to-Earnings (P/E) ratio?
Interpace Biosciences, Inc. current P/E ratio is 1.42.
Does Interpace Biosciences, Inc. (IDXGD) pay dividends?
No. Interpace Biosciences, Inc. does not pay a dividend.
What is Interpace Biosciences, Inc. (IDXGD) beta (volatility) score?
Interpace Biosciences, Inc. has a beta of 0.602, indicating lower volatility than the overall market.
